ReviewInternal and emergency medicine2013
Muscle atrophy in aging and chronic diseases: is it sarcopenia or cachexia?
Review in Internal and emergency medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Automated abdominal CT imaging biomarkers and clinical frailty measures associated with postoperative deceased-donor liver transplant outcomes.European radiology · 2025Article
- Metabolic and molecular regulation in skeletal muscle dysfunction and regeneration.Frontiers in cell and developmental biology · 2025Review
- Sarcopenia in patients with multiple myeloma and autologous hematopoietic stem cell transplantation.Northern clinics of Istanbul · 2025Article
- A Comparative Analysis of the SARC-F Questionnaire and the Malnutrition-Inflammation Score for Sarcopenia Risk Assessment and Negative Outcome Probability in Chronic Hemodialysis Patients.Journal of clinical medicine · 2024Article
- Potential of Lycii Radicis Cortex as an Ameliorative Agent for Skeletal Muscle Atrophy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies.Biomedicines · 2022Review
- Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study.World journal of clinical oncology · 2021Article
- Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly.BMC musculoskeletal disorders · 2020Article
- Some clarifications of terminology may facilitate sarcopenia assessment.Archives of medical science : AMS · 2020Article
- Sarcopenia: A Time for Action. An SCWD Position Paper.Journal of cachexia, sarcopenia and muscle · 2019Review
- Cullin-3 dependent deregulation of ACTN1 represents a new pathogenic mechanism in nemaline myopathy.JCI insight · 2019Article
- From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients.Therapeutic advances in medical oncology · 2019Review
- Quantitative analysis of skeletal muscle by computed tomography imaging-State of the art.Journal of orthopaedic translation · 2018Review
- Collagen-induced arthritis as an animal model of rheumatoid cachexia.Journal of cachexia, sarcopenia and muscle · 2018Article
- Ghrelin therapy improves lung and cardiovascular function in experimental emphysema.Respiratory research · 2017Article
- Apigenin enhances skeletal muscle hypertrophy and myoblast differentiation by regulating Prmt7.Oncotarget · 2017Article
- Epidemiology of Sarcopenia: Determinants Throughout the Lifecourse.Calcified tissue international · 2017Review
- Epidemiology of sarcopenia and insight into possible therapeutic targets.Nature reviews. Rheumatology · 2017Review
- The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature.The oncologist · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cachexia and sarcopenia present several analogies in both the pathogenic mechanisms and the clinical picture. The loss of muscle mass and strength is a hallmark of these two clinical conditions. Although frequently overlapping and often indistinguishable, especially in old individuals, these two conditions should be considered distinct clinical entities. A prompt and accurate patient evaluation, guiding the physician through a proper differential diagnostic procedure and providing the best therapeutic options, is recommended. Given the several commonalities between cachexia and sarcopenia, it is likely that the therapeutic approaches may prove effective in both conditions. This review focuses on the most recent available literature and aims at providing physicians with the correct tools that are available to aid in diagnosing these two different entities that often clinically overlap. Currently available or proposed therapeutic strategies for pre-cachexia, cachexia and sarcopenia are also briefly described.
Indexed as
Identifiers
22773188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.